Renjie Jin1, Connor Forbes1, Nicole L Miller1, Douglas Strand2, Thomas Case1, Justin M Cates3, Hye-Young H Kim4, Phillip Wages4, Ned A Porter4, Krystin M Mantione5, Sarah Burke5, James L Mohler5,6, Robert J Matusik1. 1. Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 2. Department of Urology, University of Texas, Southwestern, Dallas, Texas, USA. 3. Department of Pathology Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 4. Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA. 5. Bioanalytics, Metabolomics, and Pharmacokinetics Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. 6. Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Abstract
BACKGROUND: The development of benign prostatic hyperplasia (BPH) and medication-refractory lower urinary tract symptoms (LUTS) remain poorly understood. This study attempted to characterize the pathways associated with failure of medical therapy for BPH/LUTS. METHODS: Transitional zone tissue levels of cholesterol and steroids were measured in patients who failed medical therapy for BPH/LUTS and controls. Prostatic gene expression was measured using qPCR and BPH cells were used in organoid culture to study prostatic branching. RESULTS: BPH patients on 5-α-reductase inhibitor (5ARI) showed low levels of tissue dihydrotestosterone (DHT), increased levels of steroid 5-α-reductase type II (SRD5A2), and diminished levels of androgen receptor (AR) target genes, prostate-specific antigen (PSA), and transmembrane serine protease 2 (TMPRSS2). 5ARI raised prostatic tissue levels of glucocorticoids (GC), whereas alpha-adrenergic receptor antagonists (α-blockers) did not. Nuclear localization of GR in prostatic epithelium and stroma appeared in all patient samples. Treatment of four BPH organoid cell lines with dexamethasone, a synthetic GC, resulted in budding and branching. CONCLUSIONS: After failure of medical therapy for BPH/LUTS, 5ARI therapy continued to inhibit androgenesis but a 5ARI-induced pathway increased tissue levels of GC not seen in patients on α-blockers. GC stimulation of organoids indicated that the GC receptors are a trigger for controlling growth of prostate glands. A 5ARI-induced pathway revealed GC activation can serve as a master regulator of prostatic branching and growth.
BACKGROUND: The development of benign prostatic hyperplasia (BPH) and medication-refractory lower urinary tract symptoms (LUTS) remain poorly understood. This study attempted to characterize the pathways associated with failure of medical therapy for BPH/LUTS. METHODS: Transitional zone tissue levels of cholesterol and steroids were measured in patients who failed medical therapy for BPH/LUTS and controls. Prostatic gene expression was measured using qPCR and BPH cells were used in organoid culture to study prostatic branching. RESULTS: BPH patients on 5-α-reductase inhibitor (5ARI) showed low levels of tissue dihydrotestosterone (DHT), increased levels of steroid 5-α-reductase type II (SRD5A2), and diminished levels of androgen receptor (AR) target genes, prostate-specific antigen (PSA), and transmembrane serine protease 2 (TMPRSS2). 5ARI raised prostatic tissue levels of glucocorticoids (GC), whereas alpha-adrenergic receptor antagonists (α-blockers) did not. Nuclear localization of GR in prostatic epithelium and stroma appeared in all patient samples. Treatment of four BPH organoid cell lines with dexamethasone, a synthetic GC, resulted in budding and branching. CONCLUSIONS: After failure of medical therapy for BPH/LUTS, 5ARI therapy continued to inhibit androgenesis but a 5ARI-induced pathway increased tissue levels of GC not seen in patients on α-blockers. GC stimulation of organoids indicated that the GC receptors are a trigger for controlling growth of prostate glands. A 5ARI-induced pathway revealed GC activation can serve as a master regulator of prostatic branching and growth.
Authors: Claus G Roehrborn; Paul Siami; Jack Barkin; Ronaldo Damião; Kim Major-Walker; Indrani Nandy; Betsy B Morrill; R Paul Gagnier; Francesco Montorsi Journal: Eur Urol Date: 2009-09-19 Impact factor: 20.096
Authors: Magdalena M Grabowska; Stephen M Kelly; Amy L Reese; Justin M Cates; Tom C Case; Jianghong Zhang; David J DeGraff; Douglas W Strand; Nicole L Miller; Peter E Clark; Simon W Hayward; Richard M Gronostajski; Philip D Anderson; Robert J Matusik Journal: Endocrinology Date: 2015-12-17 Impact factor: 4.736
Authors: Maryam Nasiri; Nikolaos Nikolaou; Silvia Parajes; Nils P Krone; George Valsamakis; George Mastorakos; Beverly Hughes; Angela Taylor; Iwona J Bujalska; Laura L Gathercole; Jeremy W Tomlinson Journal: Endocrinology Date: 2015-05-14 Impact factor: 4.736
Authors: Antoine Reginensi; Leonie Enderle; Alex Gregorieff; Randy L Johnson; Jeffrey L Wrana; Helen McNeill Journal: Nat Commun Date: 2016-08-02 Impact factor: 14.919